The binding of α1-AR antagonists to these receptors counteracts Gq-activated InositolTrisPhosphate/calcium/Myosin Light Chain Kinase pathway and leads to relaxation of smooth muscles, making α1-AR antagonists efficient drugs to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia (BPH). The gene discussed is MYH14; the disease is benign prostatic hyperplasia.